Drug intelligence / Profile preview

famotidine + loratadine

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

A combination of two histamine receptor antagonists that work on different receptors. Famotidine is an H2 receptor antagonist primarily used to reduce gastric acid secretion, while loratadine is a second-generation H1 receptor antagonist used for allergic conditions. This combination targets both H1 and H2 histamine receptors, potentially providing more comprehensive relief for conditions involving histamine-related symptoms.

Targets

HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on famotidine + loratadine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on famotidine + loratadine.

Explore the full profile